In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
US biotech Iovance Biotherapeutics saw its shares drop more than 20% on Tuesday, after it revealed a setback with its clinical program for LN-145 TIL therapy in non-small lung cancer (NSCLC). 29 December 2023
Biotechnology
US oncology drug developer Oncternal Therapeutics took a 10% initial tumble after it revealed a patient in an early-stage trial of its ONCT-808, but closed the day up 18% at $0.59. 29 December 2023
Biotechnology
Singapore-based Novotech, an Asia-Pacific-focused contract research organization (CRO), has presented research on financial shifts in the biotech industry in 2023. 29 December 2023
Biotechnology
Vertex Pharmaceuticals and CRISPR Therapeutics made history last month by gaining approval for the first CRISPR-based drug, Casgevy (exagamglogene autotemcel). 29 December 2023
Pharmaceutical
Russia may be faced with a shortage of some important antibiotics next year due to the recent decision of some global drugmakers to withdraw them from the market, The Pharma Letter’s local correspondent reports. 29 December 2023
Biotechnology
Just a few days after punting $14 billion to acquire Karuna, Bristol Myers Squibb has announced a definitive agreement to take over radiopharmaceuticals-focused drug developer RayzeBio. 28 December 2023
Biotechnology
Privately-held Chinese firm Elpiscience Biopharma has inked a deal with Japan’s Astellas Pharma related to two novel bi-specific macrophage engagers (BiME). 28 December 2023
Generics
India's aspiration for pharmaceutical self-reliance hit a rough patch as recent data indicates a surge in imports of bulk drugs and intermediates from various countries, including China, over the past two years. 28 December 2023
Biotechnology
Chinese biopharma Innovent Biologics and Xuanzhu Biopharma have entered into a clinical trial collaboration and supply accord for the combination therapies of Tyvyt (sintilimab) injection with KM-501. 28 December 2023
Pharmaceutical
Californian biotech Amgen has announced that the US Food and Drug Administration has rejected its bid for full approval of Lumakras (sotorasib). 28 December 2023
Biotechnology
The level of competition in the Russian pharmaceutical market will significantly tighten next year, as local drugmakers plan to overtake global producers in the segment of public procurements, reports The Pharma Letter’s local correspondent. 28 December 2023
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12. 28 December 2023
Pharmaceutical
The market for Gaucher disease is set to experience a compound annual growth rate (CAGR) of 0.79% across the seven major markets from $1.2 billion in 2022 to $1.3 billion in 2032. 28 December 2023
Biotechnology
Shares in US muscle biology specialist Cytokinetics soared 70% to $77.34 this morning, as it announced positive results from the much-awaited SEQUOIA trial of its aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). 27 December 2023
Biotechnology
Beijing-based Biocytogen Pharmaceuticals has inked a deal with Spanish cancer company Ona Therapeutics. 27 December 2023
Biotechnology
Japan’s innovative pharma market has been on an upwards trajectory these last 12 months – despite what you may have seen in IQVIA thought leadership reports, industry advocacy body pronouncements or USD-reported results. 27 December 2023
Biotechnology
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Bimzelx (bimekizumab) for the treatment of adults with psoriatic arthritis (PsA), non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) who are not sufficiently responding to existing treatments, said Belgian drugmaker UCB. 27 December 2023
Biotechnology
Canadian biotech Zymeworks revealed it has entered into a securities purchase agreement with funds affiliated with EcoR1 Capital for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par value per share, in a private placement. 27 December 2023
Biotechnology
In a bid to further its cell therapy ambitions, UK pharma major AstraZeneca has entered into a definitive agreement to acquire China’s clinical-stage biotech Gracell Biotechnologies 26 December 2023
Biotechnology
AlloVir on Friday saw its shares plunge more than 67% to $0.77, after it announced discontinuation of its three Phase III studies for its lead asset posoleucel, an allogeneic T cell immunotherapy company. 26 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze